COMPASS: A computational model to predict changes in MMSE scores 24-months after initial assessment of Alzheimer’s disease

We present COMPASS, a COmputational Model to Predict the development of Alzheimer’s diSease Spectrum, to model Alzheimer’s disease (AD) progression. This was the best-performing method in recent crowdsourcing benchmark study, DREAM Alzheimer’s Disease Big Data challenge to predict changes in Mini-Mental State Examination (MMSE) scores over 24-months using standardized data. In the present study, we conducted three additional analyses beyond the DREAM challenge question to improve the clinical contribution of our approach, including: (1) adding pre-validated baseline cognitive composite scores of ADNI-MEM and ADNI-EF, (2) identifying subjects with significant declines in MMSE scores, and (3) incorporating SNPs of top 10 genes connected to APOE identified from functional-relationship network. For (1) above, we significantly improved predictive accuracy, especially for the Mild Cognitive Impairment (MCI) group. For (2), we achieved an area under ROC of 0.814 in predicting significant MMSE decline: our model has 100% precision at 5% recall, and 91% accuracy at 10% recall. For (3), “genetic only” model has Pearson’s correlation of 0.15 to predict progression in the MCI group. Even though addition of this limited genetic model to COMPASS did not improve prediction of progression of MCI group, the predictive ability of SNP information extended beyond well-known APOE allele.

[1]  A. Kaszniak,et al.  Clinical trial of indomethacin in Alzheimer's disease , 1993, Neurology.

[2]  Jeffrey L. Cummings,et al.  The spectrum of behavioral changes in Alzheimer's disease , 1996, Neurology.

[3]  B. Winblad,et al.  Costs of dementia and dementia care: a review , 1997, International journal of geriatric psychiatry.

[4]  L. Thal,et al.  Clinical Dementia Rating training and reliability in multicenter studies , 1997, Neurology.

[5]  Thorsten Joachims,et al.  Making large scale SVM learning practical , 1998 .

[6]  Elizabeth M. Smigielski,et al.  dbSNP: a database of single nucleotide polymorphisms , 2000, Nucleic Acids Res..

[7]  H. Soininen,et al.  Three-year follow-up of cerebrospinal fluid tau, beta-amyloid 42 and 40 concentrations in Alzheimer's disease. , 2000, Neuroscience letters.

[8]  H. Soininen,et al.  Three-year follow-up of cerebrospinal fluid tau, β-amyloid 42 and 40 concentrations in Alzheimer's disease , 2000, Neuroscience Letters.

[9]  J. Touchon,et al.  Classification criteria for mild cognitive impairment , 2001, Neurology.

[10]  Carole Dufouil,et al.  Depressive symptoms and cognitive decline in elderly people. Longitudinal study. , 2002, The British journal of psychiatry : the journal of mental science.

[11]  P.4.014 Correlation of depressive symptoms and cognitive decline in elderly people , 2003, European Neuropsychopharmacology.

[12]  D. Bennett,et al.  Religious Orders Study: Overview and Change in Cognitive and Motor Speed , 2004 .

[13]  David A. Bennett,et al.  The Rush Memory and Aging Project: Study Design and Baseline Characteristics of the Study Cohort , 2005, Neuroepidemiology.

[14]  Yaakov Stern,et al.  Cognitive reserve and Alzheimer disease. , 2006, Alzheimer disease and associated disorders.

[15]  Y. Stern.  Cognitive Reserve and Alzheimer Disease , 2006, Alzheimer disease and associated disorders.

[16]  R. Petersen,et al.  Mild cognitive impairment , 2006, The Lancet.

[17]  S. Riedel-Heller,et al.  Measuring cognitive change in older adults: reliable change indices for the Mini-Mental State Examination , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

[18]  A. Califano,et al.  Dialogue on Reverse‐Engineering Assessment and Methods , 2007, Annals of the New York Academy of Sciences.

[19]  P. Scheltens,et al.  Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria , 2007, The Lancet Neurology.

[20]  Yuanfang Guan,et al.  A Genomewide Functional Network for the Laboratory Mouse , 2008, PLoS Comput. Biol..

[21]  C. Bulpitt,et al.  Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial , 2008, The Lancet Neurology.

[22]  A. Burns.  Alzheimer's disease: on the verges of treatment and prevention , 2009, The Lancet Neurology.

[23]  J. Brewer,et al.  High-throughput, Fully Automated Volumetry for Prediction of MMSE and CDR Decline in Mild Cognitive Impairment , 2009, Alzheimer disease and associated disorders.

[24]  Ian H. Witten,et al.  The WEKA data mining software: an update , 2009, SKDD.

[25]  D. Selkoe.  Alzheimer's disease. , 2011, Cold Spring Harbor perspectives in biology.

[26]  Denise C. Park,et al.  Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[27]  J. Trojanowski,et al.  Prediction of MCI to AD conversion, via MRI, CSF biomarkers, and pattern classification , 2011, Neurobiology of Aging.

[28]  H. Dodge,et al.  Risk of Alzheimer's disease incidence attributable to vascular disease in the population , 2011, Alzheimer's & Dementia.

[29]  Yuanfang Guan,et al.  Tissue-Specific Functional Networks for Prioritizing Phenotype and Disease Genes , 2012, PLoS Comput. Biol..

[30]  Philip S. Insel,et al.  Development and assessment of a composite score for memory in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) , 2012, Brain Imaging and Behavior.

[31]  M. Glymour,et al.  Relationship between baseline brain metabolism measured using [18F]FDG PET and memory and executive function in prodromal and early Alzheimer’s disease , 2012, Brain Imaging and Behavior.

[32]  Malcolm Atkinson,et al.  Computed tomography perfusion imaging denoising using Gaussian process regression , 2012, Physics in medicine and biology.

[33]  Philip S. Insel,et al.  A composite score for executive functioning, validated in Alzheimer’s Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment , 2012, Brain Imaging and Behavior.

[34]  W. Maier,et al.  Assessing cognitive changes in the elderly: Reliable Change Indices for the Mini‐Mental State Examination , 2012, Acta psychiatrica Scandinavica.

[35]  Jerry L. Prince,et al.  A computational neurodegenerative disease progression score: Method and results with the Alzheimer's disease neuroimaging initiative cohort , 2012, NeuroImage.

[36]  Daoqiang Zhang,et al.  Predicting Future Clinical Changes of MCI Patients Using Longitudinal and Multimodal Biomarkers , 2012, PloS one.

[37]  Shannon L. Risacher,et al.  Voxel and surface-based topography of memory and executive deficits in mild cognitive impairment and Alzheimer’s disease , 2012, Brain Imaging and Behavior.

[38]  A. Wimo,et al.  The global prevalence of dementia: A systematic review and metaanalysis , 2013, Alzheimer's & Dementia.

[39]  Joanna M. Wardlaw,et al.  Lesion Area Detection Using Source Image Correlation Coefficient for CT Perfusion Imaging , 2013, IEEE Journal of Biomedical and Health Informatics.

[40]  J. Weuve,et al.  Alzheimer disease in the United States (2010–2050) estimated using the 2010 census , 2013, Neurology.

[41]  D. Harvey,et al.  Biomarker progressions explain higher variability in stage-specific cognitive decline than baseline values in Alzheimer disease , 2014, Alzheimer's & Dementia.

[42]  Hongdong Li,et al.  Modeling dynamic functional relationship networks and application to ex vivo human erythroid differentiation , 2014, Bioinform..

[43]  Fan Zhu,et al.  Regulatory network inferred using expression data of small sample size: application and validation in erythroid system , 2015, Bioinform..

[44]  C. Jack,et al.  Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria , 2016, Alzheimer's & Dementia.

[45]  Michael W. Weiner,et al.  Crowdsourced estimation of cognitive decline and resilience in Alzheimer's disease , 2016, Alzheimer's & Dementia.